Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
Read Article
News
2024
2023
Archive
Search news articles
March 17, 2017
VIVEVE ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK
March 13, 2017
HOMOLOGY MEDICINES AND NOVARTIS ENTER COLLABORATION TO DEVELOP NEW TREATMENTS USING HOMOLOGY’S PROPRIETARY GENE EDITING TECHNOLOGY
March 13, 2017
NOUSCOM’S NEOANTIGEN-BASED VACCINE SYNERGIZES WITH NKTR-214 TO CURE ESTABLISHED TUMORS IN PRECLINICAL MODEL
February 28, 2017
GENEPEEKS ANNOUNCES ADDITIONAL PARTNERSHIPS WITH THE DONOR SOLUTION AND 3 SISTERS SURROGACY
February 22, 2017
5AM FOUNDING PARTNER JOHN DIEKMAN NAMED AS NEW CHAIRMAN OF THE SCRIPPS RESEARCH INSTITUTE IN LA JOLLA
February 21, 2017
CIDARA THERAPEUTICS REPORTS UNFAVORABLE RESULTS OF PHASE 2 RADIANT TRIAL OF CD101 TOPICAL IN VVC
February 20, 2017
BAY AREA’S KINESTRAL, VIEW SEE CLEAR FUTURE IN SMART WINDOWS
February 17, 2017
ARVINAS PRESENTS NEW PRECLINICAL DATA ON ORAL ANDROGEN RECEPTOR PROTAC AT ASCO 2017 GENITOURINARY CANCERS SYMPOSIUM
February 7, 2017
NOHLA THERAPEUTICS APPOINTS KATHLEEN FANNING AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
February 6, 2017
SPYRYX BIOSCIENCES ANNOUNCES SUCCESSFUL COMPLETION OF PHASE 1 CLINICAL TRIAL FOR SPX-101 AND PLANNED PHASE 2 INITIATION IN CYSTIC FIBROSIS DURING 2017
« Previous Page
1
…
5
6
7
8
Next Page »